BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec
This article was originally published in PharmAsia News
Executive Summary
South Korea's SillaJen, which has ambitions to launch its oncolytic virus-based immunotherapy Pexa-Vec in global markets in the next few years, has unveiled progress of its global Phase III study and the company's global strategy during the recent BIO Korea 2016 in Seoul.
You may also be interested in...
Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors
Samsung BioLogics has set out plans for one of the biggest ever IPOs in South Korea that could help reignite investor sentiment battered by recent events surrounding Hanmi.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.